Changes in Hong Kong stocks | Siludi Pharmaceutical Co., Ltd. (01244) rose nearly 7%, and Envida was certified as an orphan drug for gastric cancer and gastroesophageal junction cancer indications

Zhitongcaijing · 2d ago

The Zhitong Finance App learned that Siludi Pharmaceutical Co., Ltd. (01244) rose nearly 7%. As of press release, it had risen 6.77% to HK$4.73, with a turnover of HK$911,200.

According to the news, on the evening of December 22, Siludi Pharmaceutical Co., Ltd. announced that its commercial product Enveda® (generic name: Envolizumab injection, original research code: KN035) was officially certified as an orphan drug for gastric cancer and gastroesophageal conjunct cancer. This is the third orphan drug indication successfully approved after being indicated for cholangiocarcinoma and soft tissue sarcoma.

The phase II clinical study of advanced gastroesophagastric adenocarcinoma approved by the company showed clear anti-tumor efficacy. The objective response rate in combination with FOLFOX was 60%, the disease control rate was as high as 100%, and the safety and tolerability were good, and there were no adverse events leading to termination of treatment or death.